Premium
Testing the Chemosensitivity of Renal Carcinoma in vitro
Author(s) -
LAI TERESA,
FERRO M.A.,
KAISARY A. V.,
SMITH P.J. B.,
SYMES M.O.
Publication year - 1989
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1989.tb05517.x
Subject(s) - vinblastine , doxorubicin , methotrexate , in vivo , in vitro , pharmacology , chemosensitivity assay , drug , carcinoma , kidney , renal carcinoma , medroxyprogesterone , medicine , chemistry , medroxyprogesterone acetate , cancer research , chemotherapy , pathology , biology , biochemistry , microbiology and biotechnology , hormone
Summary— Tumour cells from 23 renal carcinomas were exposed in vitro to increasing concentrations of medroxyprogesterone acetate (MPA) or one of several cytotoxic agents. Thereafter the uptake of 75 Selenomethionine ( 75 SeM) was compared to that of tumour cells not exposed to the drug. Using drug concentrations similar to those seen following in vivo administration in patients, MPA produced 50% inhibition of 75 SeM uptake in 5 of 23 cases. The comparable proportion for doxorubicin was 4 of 5 and for mitozantrone 7 of 12. Methotrexate and Vinblastine were much less effective. In all cases where 2 50% inhibition was obtained with doxorubicin and mitozantrone the carcinoma had spread beyond the kidney. Thus drug sensitivity may be associated with a high mitotic rate.